Premium
Silver carbene complexes: An emerging class of anticancer agents
Author(s) -
Kankala Shravankumar,
Thota Niranjan,
Björkling Fredrik,
Taylor Myles K.,
Vadde Ravinder,
Balusu Ramesh
Publication year - 2019
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21478
Subject(s) - carbene , cancer , mechanism (biology) , mechanism of action , cancer therapy , chemistry , computational biology , pharmacology , medicine , bioinformatics , cancer research , nanotechnology , in vitro , biology , biochemistry , materials science , philosophy , epistemology , catalysis
Cancer is a major global health problem with large therapeutic challenges. Although substantial progress has been made in cancer therapy, there still remains a need to develop novel and effective treatment strategies to treat several relapsed and refractory cancers. Recently, there has been growing demand for considering organometallics as antineoplastic agents. This review is focused on a group of organometallics, silver N ‐heterocyclic carbene complexes (SCCs) and their anticancer efficacy in targeting multiple pathways in various in vitro cancer model systems. However, the precise molecular mechanism of SCCs anticancer properties remains unclear. Here, we discuss the SCCs chemistry, potential molecular targets, possible molecular mechanism of action, and their application in cancer therapies.